

AFFYMAX INC  
Form 8-K  
February 14, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 13, 2013**

**AFFYMAX, INC.**

(Exact name of registrant as specified in charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-33213**  
(Commission File Number)

**77-0579396**  
(I.R.S. Employer Identification No.)

**4001 Miranda Avenue**  
**Palo Alto, California 94304**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 812 -8700**

---

## Edgar Filing: AFFYMAX INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

On February 13, 2013, Fresenius Medical Care North America ( FMCNA ) communicated that it has accumulated experience with OMONTYS® (peginesatide) Injection in more than 56,600 administrations in over 18,000 patients in its dialysis facilities and that it will pause further expansion of the OMONTYS pilot that began in late July 2012. FMCNA has indicated that it will analyze the full set of efficacy and safety profile information and that the current scale of their experience with use of OMONTYS is adequate to complete this analysis.

The FMCNA memoranda is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statement and Exhibits.**

(d) Exhibits:

Exhibit No.	Description
99.1	FMCNA Memoranda dated February 13, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**AFFYMAX, INC .**

Dated: February 14, 2013

By:

/s/ Grace U. Shin  
Grace U. Shin  
General Counsel